Current NASPGHAN guidelines recommend lifestyle modifications as the first-line intervention for the management of NAFLD and the use of ALT decrease or normalization as an acceptable surrogate in NAFLD treatment. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.